Welcome to our dedicated page for Dexcom news (Ticker: DXCM), a resource for investors and traders seeking the latest updates and insights on Dexcom stock.
DexCom, Inc. (DXCM) is widely described in its own communications as a global leader in glucose biosensing and real-time continuous glucose monitoring (CGM) for people with diabetes. The Dexcom news stream features regular updates on product launches, clinical evidence, coverage decisions, financial performance, and leadership developments, all centered on its CGM and biosensing technology.
Investors and healthcare observers following DXCM news will find detailed announcements on new products such as the Dexcom G7 15 Day CGM System, which is designed to provide real-time glucose readings over extended wear, and Dexcom Smart Basal, a CGM-integrated basal insulin dosing optimizer for adults with Type 2 diabetes using long-acting insulin. News items also cover enhancements to the Stelo app for metabolic health, AI-enabled features like meal logging, and integrations with connected devices and insulin delivery systems.
Dexcom’s news releases highlight clinical and real-world data presented at major conferences, including the European Association for the Study of Diabetes (EASD), where the company shares findings on outcomes such as pregnancy complications, diabetic ketoacidosis management, and cost-effectiveness of CGM compared to fingersticks. Coverage and reimbursement milestones, such as expanded access under the Régie de l’assurance maladie du Québec (RAMQ) and other public programs, are also frequent topics.
Financial results and guidance updates, leadership transitions, and board appointments are reported through earnings releases and Form 8-K related press announcements. For anyone tracking how CGM technology, biosensing, and digital health tools are evolving in diabetes and metabolic health, the Dexcom news page offers an ongoing record of the company’s product, clinical, and corporate developments. Bookmark this page to follow the latest DXCM press releases and regulatory disclosures as they are issued.
Dexcom, Inc. (NASDAQ: DXCM) announced that its G6 continuous glucose monitoring (CGM) system is now eligible for public coverage in Prince Edward Island’s Diabetes Glucose Sensor Program for type 1 and type 2 diabetes patients aged two and older who are on multiple daily insulin injections or use insulin pumps. This expands access to advanced diabetes management technology, which has been proven to improve glycemic control and reduce long-term complications. The program joins other provinces in providing publicly funded coverage, aiming to enhance quality of life for Canadians living with diabetes.
DexCom, Inc. (NASDAQ:DXCM) has addressed recent media speculation regarding potential mergers and acquisitions. The company confirms it is currently not in active discussions about a merger transaction. This statement comes in the context of ongoing rumors and the approaching American Diabetes Association conference. DexCom's management emphasized their regular review of opportunities to enhance stockholder value but will not comment further on this matter unless circumstances change.
DexCom, Inc. (NASDAQ:DXCM) announced that Brice Bobzien, Senior Vice President of Finance, will present an update at the Piper Sandler Ophthalmology and Diabetes Symposium on May 25, 2022, at 1:00 p.m. EDT. The presentation will be accessible via webcast on the Dexcom Investor Relations website, where it will also be archived for future viewing.
Headquartered in San Diego, California, DexCom leads in diabetes care technology through innovative continuous glucose monitoring products.
DexCom, Inc. (NASDAQ:DXCM) has announced that Jereme Sylvain, Executive Vice President and CFO, will present updates at two upcoming investor conferences. The first is the BofA Securities 2022 Healthcare Conference on May 11, 2022, at 5:40 PM (EST), and the second is the William Blair 42nd Annual Growth Stock Conference on June 8, 2022, at 5:00 PM (EST). Webcasts for these events will be available on the DexCom Investor Relations website and archived for future access.
DexCom announces an update regarding its first quarter 2022 earnings call, rescheduling it to start at 5:30 p.m. ET due to technical difficulties with the conference call provider. The link for the webcast will be available on the DexCom investor relations website and will be archived for future reference. Investors can listen to the call by dialing the provided numbers and using the confirmation number.
DexCom continues to focus on empowering diabetes management through innovative continuous glucose monitoring (CGM) systems, emphasizing its leadership in diabetes care technology.
DexCom, Inc. (Nasdaq: DXCM) reported a 25% revenue growth in Q1 2022, reaching $628.8 million. U.S. revenue rose 18% while international revenue surged 43%. GAAP operating income was $41.3 million (6.6% of revenue), down from the previous year. The company reaffirmed its 2022 revenue guidance of $2.82 - 2.94 billion and outlined strategic initiatives, including the limited launch of the Dexcom G7 in Europe and new market expansions. Cash reserves stood at $2.69 billion, providing strong financial flexibility.
DexCom, the leader in continuous glucose monitoring (CGM), introduced its new product portfolio at the ATTD conference, showcasing the Dexcom ONE, Dexcom G6, and the FDA-reviewed Dexcom G7. These systems aim to enhance diabetes management with features like real-time monitoring and customizable alerts. The Dexcom ONE is now accessible in Spain and will launch in the UK this May. The offerings emphasize innovation and connectivity, designed to cater to diverse diabetes needs.
Summary not available.
DexCom, Inc. (NASDAQ:DXCM) announced that its new Dexcom ONE Continuous Glucose Monitoring System will launch in the UK this May. Currently under review for addition to the NHS Drug Tariff, this system aims to enhance accessibility for diabetes management. The NICE has recommended offering glucose sensors to Type 1 diabetes patients based on individual needs, promoting better health outcomes. Dexcom ONE features a user-friendly app for real-time glucose monitoring, reducing the need for fingerpricks and improving treatment decisions.
DexCom, Inc. (NASDAQ:DXCM) announced plans to release its first quarter 2022 financial results after the market closes on Thursday, April 28, 2022. A conference call will be held at 4:30 p.m. (ET) to discuss the results, with a live webcast available on the investor relations website.
DexCom, based in San Diego, California, is a leader in continuous glucose monitoring systems, aiming to improve diabetes management globally.
FAQ
What is the current stock price of Dexcom (DXCM)?
What is the market cap of Dexcom (DXCM)?
